21
Nov 24
20
Nov 24
13
Nov 24
07
Nov 24
30
Oct 24
30
Oct 24
30
Oct 24
28
Oct 24
16
Oct 24
03
Sep 24
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
LA JOLLA, Calif. , Nov. 21, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and
CalciMedica Announces Presentations at Upcoming Medical Meetings
Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting LA JOLLA, Calif. , Nov.
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE trial in acute kidney injury (AKI) and in Phase 2
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. ( CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and
CalciMedica Announces Pricing of Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and
CalciMedica Announces Proposed Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET / 9 a.m. PT LA JOLLA, Calif. , Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
Displaying 1 - 10 of 25